- Paxlovid was found to have no significant benefit in improving Long Covid symptoms, a new study published in JAMA Internal Medicine found. Researchers at Stanford University gave the antiviral drug, used to treat Covid-19, to over a hundred participants for 15 days. Another Paxlovid clinical trial from the NIH’s RECOVER program is currently underway testing the drug for 25 days. Read commentary about the study from Long Covid researcher Michael Peluso, who was not affiliated with the study but is currently leading a study on the antiviral ensitrelvir.
- A new systematic review of 36 high-quality studies found a “high frequency” of cognitive impairment following Covid-19 infection. “The cognitive abilities most often impaired were executive functions, attention, and memory,” the study’s authors wrote, noting that the ability to use language has not been properly investigated. These findings showed that these cognitive impairments greatly affected the independence and quality of life of people with Long Covid.
- A small clinical trial is recruiting to test the drug Tonabersat (Xiflam), a gap junction modulator that has been found to prevent inflammatory damage in the central nervous system. The drug is also being investigated separately as a potential treatment for migraines. The Long Covid trial will test the drug daily for 12 weeks. It is recruiting 15 participants in Waltham, Massachusetts. Find more clinical trials at Long Covid Studies.
Leave a Reply